Search results for "chronic kidney disease"
showing 10 items of 119 documents
Pericardial thickening in chronic kidney disease: what meaning?
2010
Impact of diabetes on left ventricular geometry in hypertensive patients with chronic kidney disease
2009
Relationship between fetuin-A, glomerular filtration rate and endothelial dysfunction in hypertensive patients with moderate to severe chronic kidney…
2009
Vitom® 3D in arterio-venous fistulas: Single centre preliminary surgical experience
2021
Background: Arteriovenous fistula (AVF) is the vascular access of choice for hemodialysis patients. A correct microsurgical vascular anastomoses is essential to the optimal care of patients. Loupes can help surgeons perform such procedures, but often cause neck or back pain and fatigue. Aim: This study aimed to evaluate whether a video telescopic operating microscope (VITOM®; Karl Storz Endoscopy GmbH, Tuttlingen, Germany) could be used as a substitute for loupes to create microsurgical vascular anastomoses. Methods: We evaluated microsurgical anastomoses with VITOM® in 10 patients (6 male, 4 female) from January 2019 to December 2019. The created anastomoses were 7 side-to-side, 2 side-to-…
Incidence of hepatitis C virus infection in patients with chronic kidney disease on conservative therapy
2011
Monitoring Risk Factors and Improving Adherence to Therapy in Patients With Chronic Kidney Disease (Smit-CKD Project): Pilot Observational Study
2022
Background Chronic kidney disease is a major public health issue, with about 13% of the general adult population and 30% of the elderly affected. Patients in the last stage of this disease have an almost uniquely high risk of death and cardiovascular events, with reduced adherence to therapy representing an additional risk factor for cardiovascular morbidity and mortality. Considering the increased penetration of mobile phones, a mobile app could educate patients to autonomously monitor cardiorenal risk factors. Objective With this background in mind, we developed an integrated system of a server and app with the aim of improving self-monitoring of cardiovascular and renal risk factors and…
Advanced chronic kidney disease. Association between anxiety, depression and resilience
2019
Resumen Introducción: el padecimiento de la enfermedad renal crónica avanzada (ERCA) se asocia con una mayor probabilidad de padecer sintomatología depresiva y ansiosa. No obstante, la resiliencia puede amortiguar estos efectos. El objetivo general fue valorar la sintomatología ansiosa, depresiva y la resiliencia de los pacientes con ERCA. Métodos: 70 pacientes (80 % varones), con edades entre 38-88 años (M=68,88; DT= 9,98) fueron evaluados mediante la Escala Hospitalaria de Ansiedad y Depresión y la de Resiliencia de Connor Davidson. Se realizaron análisis descriptivos, pruebas t, d de Cohen y correlaciones de Pearson. Resultados: un 41,79 % presentó sintomatología ansiosa y un 25,38 % dep…
Diabetic Kidney Disease and COVID-19: The Crash of Two Pandemics
2020
Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment
2016
Cardiorenal syndrome type 4 (CRS type 4), or chronic renocardiac syndrome, has been defined as "chronic abnormalities in renal function leading to cardiac disease" and recognizes the extreme burden of cardiovascular disease (CVD) risk in patients with chronic kidney disease (CKD). CKD is common and increasingly recognized as a risk factor for CVD. Even though the treatment for CVD has dramatically improved over the past decades, it still takes responsibility for up to 50% of deaths in CKD patients. For this reason, patients with CKD should be thoroughly evaluated for cardiovascular risk factors that require careful management, given the significant burden of CRS type 4 on the healthcare sys…
SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
2020
Abstract Sodium–glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluationtrial. More recently, the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial showed that dapagliflozin improved CV outcomes in patients with HF with or without diabetes. Protection from HF in non-diabetics was confirmed for empagliflozin in the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Fa…